

# A randomised controlled trial of oral prednisolone for viral-wheeze in pre-school children with stratification for serum level of Eosinophil Protein X (EPX)

<b>Submission date</b> 23/01/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 23/01/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 13/03/2007	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Jonathan Grigg

**Contact details**  
University of Leicester  
Leicester Royal Infirmary  
P.O. Box 65  
Leicester  
United Kingdom  
LE2 7LX  
+44 (0)116 252 5840  
jg33@leicester.ac.uk

## Additional identifiers

**Protocol serial number**  
AM2/01/008

## Study information

## Scientific Title

### Study objectives

This study will test the hypothesis that in preschool children with viral-wheeze, those with atopic pulmonary inflammation will respond to a short course of oral corticosteroids, whereas those with a structurally based vulnerability to wheeze will not.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration.

### Primary study design

Interventional

### Study design

Randomised controlled trial

### Study type(s)

Not Specified

### Health condition(s) or problem(s) studied

Respiratory tract diseases: Asthma

### Interventions

Children passing the inclusion criteria will be divided into two groups

a. Those with presenting serum EPX levels of greater than or equal to 25 ug/l

b. Those with EPX levels <25 ug/l.

At the next episode of viral wheeze children in both groups will receive either placebo or a short course of oral prednisolone.

### Intervention Type

Drug

### Phase

Not Specified

### Drug/device/biological/vaccine name(s)

Prednisolone

### Primary outcome(s)

Outcome will be assessed by parental scoring of respiratory symptoms using a diary card.

### Key secondary outcome(s)

No secondary outcome measures

### Completion date

28/02/2002

# Eligibility

## Key inclusion criteria

Children aged between 18 and 48 months of age presenting with viral-wheeze.

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Child

## Lower age limit

18 Months

## Upper age limit

48 Months

## Sex

Not Specified

## Key exclusion criteria

No exclusion criteria

## Date of first enrolment

01/03/1999

## Date of final enrolment

28/02/2002

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

University of Leicester

Leicester

United Kingdom

LE2 7LX

# Sponsor information

## Organisation

Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)

## Funder(s)

### Funder type

Government

### Funder Name

NHS Asthma National Research and Development Programme (UK)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Abstract results</a>		01/11/2003		No	No